GH Research’s GH001 inhalable mebufotenin targets treatment-resistant depression; Phase 2b impressed and Phase 3 looms in ...
But away from the chaos onscreen, Eden McCoy spent Mother’s Day sharing something far quieter and far more personal. The ...
Phase 2b results in TRD published in JAMA Psychiatry; GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD; GH001-HV-109 U ...
GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced ...
Please provide your email address to receive an email when new articles are posted on . Somapacitan-beco improved multiple growth-related endpoints for adolescents with four types of short stature.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results